2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Sunday, October 21, 2018

4:30PM-6:00PM: Abstract Number: 937

Evidence of a Common Microglial Signature in Models of ‘Neuropsychiatric Symptoms of Systemic Lupus Erythematosus’

3S109 ACR Abstract: SLE–Animal Models (934–939)

4:30PM-6:00PM: Abstract Number: 932

Fibroblasts Senescence Is Observed in Rheumatoid and Osteoarthritic Synovial Tissues and Triggers a Pro-Inflammatory Program Ex Vivo

3S107 ACR Abstract: RA–Etiology & Pathogenesis I (928–933)

4:30PM-6:00PM: Abstract Number: 944

Gout: A Potential Risk Factor for Uveitis in the Older Adults?

3S102 ACR Abstract: Epidemiology & Pub Health I: Morbidity & Mortality (940–945)

4:30PM-6:00PM: Abstract Number: 967

Health Care Utilization for Musculoskeletal Issues during the Pre-Diagnosis Period in Psoriatic Arthritis – a Population-Based Study

3S111 ACR Abstract: Spondyloarthritis Incl PsA–Clinical II: PsA Epidemiology (964–969)

4:30PM-6:00PM: Abstract Number: 934

HIV Protease Inhibitors Cure Lupus-Prone Mice and Prevent T Helper 17 Cell-Driven Inflammation By Inhibiting CD95-Non-Apoptotic Signaling Pathway

3S109 ACR Abstract: SLE–Animal Models (934–939)

4:30PM-6:00PM: Abstract Number: 951

IFN-Gamma Production in Lyme Arthritis Synovial Tissue Promotes Differentiation of Fibroblast-like Synoviocytes into Inflammatory Effector Cells

3S104 ACR Abstract: Infection-Related Rheumatic Disease (946–951)

4:30PM-6:00PM: Abstract Number: 940

Inactivated Influenza Vaccine Prevents Respiratory Infections and Improves All-Cause and Cause-Specific Mortality in Immunosuppressed People with Autoimmune Rheumatic Diseases: Propensity Score Adjusted Cohort Study Using Data from Clinical Practice Research Datalink

3S102 ACR Abstract: Epidemiology & Pub Health I: Morbidity & Mortality (940–945)

4:30PM-6:00PM: Abstract Number: 933

Inflammation in the Hippocampus Affects Insulin-like Growth Factor-1 Receptor Signaling and Contributes to Neurological Sequelae in Rheumatoid Arthritis

3S107 ACR Abstract: RA–Etiology & Pathogenesis I (928–933)

4:30PM-6:00PM: Abstract Number: 916

Integrative Analysis of Multi-Omics Data in an Ethnically Diverse Lupus Cohort Identifies Distinct Molecular Subtypes of SLE

3S103 ACR Abstract: Genetics, Genomics & Proteomics: Precision Medicine (916–921)

4:30PM-6:00PM: Abstract Number: 930

Joint Location-Specific IL6 and JAK-STAT Signaling in Rheumatoid Arthritis (RA) Fibroblast-like Synoviocytes (FLS)

3S107 ACR Abstract: RA–Etiology & Pathogenesis I (928–933)

4:30PM-6:00PM: Abstract Number: 974

Leflunomide Versus Azathioprine for Maintenance Therapy of Lupus Nephritis: A Prospective, Multicenter, Randomized, Open-Label Clinical Trial

3S110 ACR Abstract: SLE–Clinical I: Clinical Trials (970–975)

4:30PM-6:00PM: Abstract Number: 980

Long-Term Outcome of Temporomandibular Joint Arthritis in Juvenile Idiopathic Arthritis:Results of 18-Year Follow-up in the Population-Based Nordic JIA Cohort

3S115 ACR/ARHP Abstract: Pediatric Rheum (976–981)

4:30PM-6:00PM: Abstract Number: 949

Long-Term Rheumatic and Musculoskeletal Disorders Associated to Ebola Virus Infection

3S104 ACR Abstract: Infection-Related Rheumatic Disease (946–951)

4:30PM-6:00PM: Abstract Number: 963

Long-Term Safety of Tofacitinib up to 9.5 Years: A Comprehensive Integrated Analysis of the RA Clinical Development Program

3S108 ACR Abstract: RA–Treatments II: Safety (958–963)

4:30PM-6:00PM: Abstract Number: 973

Low-Dose IL-2 Combined with Rapamycin Efficiently Promoted Disease Remission and Recovered the Balance of Th17/Regulatory T Cells in Patients with Refractory Systemic Lupus Erythematosus

3S110 ACR Abstract: SLE–Clinical I: Clinical Trials (970–975)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].